Treatment with investigational oral therapy BIIB122/DNL151 safely lowered the activity of disease biomarkers that reflect LRRK2 activity, a protein whose mutations are associated with Parkinson’s disease, according to results from two Phase 1 clinical studies.
Oral BIIB122/DNL151 Safely Lowers LRRK2 A... - Cure Parkinson's
Oral BIIB122/DNL151 Safely Lowers LRRK2 Activity in Phase 1 Trials
Written by
Kia17
To view profiles and participate in discussions please or .
5 Replies
•
They are off to a good start. Look forward to a future phase 2 trial with data on disease modifying effect.
Actual press release from Denali here:
Definitely one to watch
Thanks for posting! Very encouraging!
Hopefully this is a cure, pray 🙏🙏🙏 thanks for sharing!
Not what you're looking for?
You may also like...
Phase 3, the Lighthouse study, Biogen and Denali, LRRK2 inhibitor BIIB122; New clinical trial registered
New clinical trial registered: Biogen and Denaliti have initiated the 2nd late-stage study of...
Phase 4 study to evaluate efficacy of orally administrated Trehalose in individuals with idiopathic & LRRK2-associated Parkinsons
New clinical trial registered:
NeuromedIRCCS researchers have registered a small (N=20) open...
Oral ANVS401 Improves Patients’ Motor Skills in Phase 2 Trial
'
Once-a-day treatment with oral ANVS401 was found to significantly improve motor skills among...
Clinical Trial Highlights – an update on previously reviewed trials (Phase 3 in focus)
https://content.iospress.com/articles/journal-of-parkinsons-disease/jpd229001...
Am I Taking the Wrong Vitamin B12? Adenosylcobalamin (AdoCbl) vs Methylcobalamin (MeCbl)
Thanks to @[222784] for sharing a link to this document: Vitamin B12 modulates Parkinson’s disease...
B12 Adenosylcobalamin form inhibits LRRK2
Protective role of ibuprofen.
Stem Cells Trials
Potential Parkinson’s Treatment, CDNF, Shows Safety and Tolerability at One Year
Parkin, glutamate, NAC, mitophagy
